Online Inquiry
Adenovirus Vaccine Development Service
Adenovirus cancer vaccines are therapy that uses adenovirus as a vector to deliver specific tumor antigens to activate the body's immune system to attack cancer cells. Alfa Cytology is committed to providing a comprehensive one-stop adenovirus cancer vaccines development service tailored to our clients' requirements against prostate cancer.
Introduction to Adenovirus Vaccine
Adenoviruses (Ads) are a widely studied class of viral vectors that are ideal for use as vaccine vectors in different forms for cancer therapy. These viral vectors stimulate the immune system and help reprogram the microenvironment of "cold tumors" such as prostate cancer into "hot tumors" by triggering a T-cell mediated response against the cancer cells. Cold tumors" are those that do not elicit a strong immune response in the microenvironment, which makes it difficult for immunotherapy to work effectively.
Fig. 1 Oncolytic adenovirus-based cancer immunotherapies. (Sato-Dahlman, M., et al. 2020)
Adenoviral vaccines enhance immune cell accessibility in the tumor microenvironment through multiple mechanisms. They increase the infiltration of immune cells into the tumor, allowing cytokines and T cells to be delivered more efficiently to the tumor site. This enhanced immune response helps to overcome the immunosuppressive properties of prostate cancer, thereby improving the efficacy of immunotherapy.
Advantages of Adenoviral Vector
Stable and Easy to Manipulate Genome
Adenoviruses have a relatively stable genome, which is well understood by scientists and allows for precise gene manipulation and cloning, which facilitates the construction of viral vectors.
High In Vivo Transduction Efficiency
Adenoviruses have high in vivo transduction efficiency in humans, enabling efficient gene delivery to target cells, which is particularly important for gene therapy and vaccine development.
Mild Side Effects
Adenoviral vectors have relatively mild side effects compared to conventional therapeutic approaches. In particular, because adenoviral vectors do not integrate into the host genome, the risk of insertional mutagenesis is reduced.
Adenovirus Vaccine Development for Prostate Cancer
| Name | Phase | Condition | Clinical Trials ID | Country |
| Ad5 PSA/MUC1/Brachyury | Phase I | HRPC | NCT00583024 | USA |
| Adenovirus/PSA Vaccine | Phase II | mCRPC | NCT03481816 | USA |
Our Services
At Alfa Cytology, the background of our adenovirus-based cancer vaccine development services stems from a deep understanding of virology and oncology. Our experts have extensive experience in viral vector design, immunomodulation and antigen delivery, enabling the design of highly targeted and efficacious adenoviral cancer vaccines.
Adenovirus Selection and Optimization
Assess and modify adenoviruses to enhance their tumor-targeting specificity and immunogenicity, ensuring maximal therapeutic impact.
Immune Response Monitoring
Employ cutting-edge assays and technologies to monitor immune responses induced by adenovirus-based cancer vaccines, guiding iterative refinement of vaccine formulations.
Prostate cancer modeling services provide researchers and pharmaceutical companies with reliable, reproducible and physiologically relevant models.
Workflow of Adenovirus Vaccine Development
Selection of Target Antigens
Vaccine Design
In vitro and Animal Model Testing
If you are looking to develop innovative adenovirus vaccine for prostate cancer, our expert team provide comprehensive support. By partnering with us, you'll receive personalized consulting services and efficient project advancement. If you are interested in our services, please don't hesitate to contact us for further information and pricing details.
Reference
- Sato-Dahlman, M., et al. Adenovirus and Immunotherapy: Advancing Cancer Treatment by Combination. Cancers. 2020, 12(5): 1295.
For research use only.